The estimated Net Worth of Laurence Reid is at least $7.11 Milhão dollars as of 31 December 2014. Laurence Reid owns over 17,000 units of Alnylam Pharmaceuticals Inc stock worth over $5,475,229 and over the last 14 years Laurence sold ALNY stock worth over $1,633,224.
Laurence has made over 10 trades of the Alnylam Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Laurence exercised 17,000 units of ALNY stock worth $271,830 on 31 December 2014.
The largest trade Laurence's ever made was selling 20,400 units of Alnylam Pharmaceuticals Inc stock on 19 February 2014 worth over $1,633,224. On average, Laurence trades about 5,699 units every 58 days since 2010. As of 31 December 2014 Laurence still owns at least 20,905 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Laurence Reid stock trades at the bottom of the page.
Laurence's mailing address filed with the SEC is 300 THIRD STREET, , CAMBRIDGE, MA, 02142.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal, eKevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: